CoChat

Accelerating Biomarker Discovery Through Electronic Health Records, Automated Biobanking, and Proteomics

Open access
Wells, Quinn S., Gupta, Deepak K., Smith, J. Gustav, Collins, Sean P., Storrow, Alan B., Ferguson, Jane, Smith, Maya Landenhed, Pulley, Jill M., Collier, Sarah, Wang, Xiaoming, Roden, Dan M., Gerszten, Robert E., Wang, Thomas J. · 2019 · Journal of the American College of Cardiology
Cited by 51

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Background: Circulating biomarkers can facilitate diagnosis and risk stratification for complex conditions such as heart failure (HF). Newer molecular platforms can accelerate biomarker discovery, but they require significant resources for data and sample acquisition. Objectives: To test a pragmatic biomarker discovery strategy integrating automated clinical biobanking with proteomics. Methods: Using the EHR, we identified patients with and without HF, retrieved their discarded plasma samples, and screened these specimens using a DNA aptamer-based proteomic platform (1,129 proteins). Candidate biomarkers were validated in three different prospective cohorts. Results: In an automated manner, plasma samples from 1,315 patients (31% with HF) were collected. Proteomic analysis of a 96-patient subset identified nine candidate biomarkers (p <4.42 × 10−5). Two proteins, angiopoietin-2 and thrombospondin-2, were associated with HF in three separate validation cohorts. In an emergency department-based registry of 852 dyspneic patients, the 2 biomarkers improved discrimination of acute HF compared with a clinical score (p <0.0001) or clinical score plus B-type natriuretic peptide (p=0.02). In a community-based cohort (n = 768), both biomarkers predicted incident HF independent of traditional risk factors and NTproBNP (HR per SD increment, 1.35 [95%CI, 1.14 to 1.61, p = 0.0007] for angiopoietin-2, and 1.37 [1.06–1.79, p = 0.02] for thrombospondin-2). Among 30 advanced HF patients, concentrations of both biomarkers declined (80–84%) following cardiac transplant (p <0.001 for both). Conclusions: A novel strategy integrating EHRs, discarded clinical specimens, and proteomics identified two biomarkers that robustly predict HF across diverse clinical settings. This approach could accelerate biomarker discovery for many diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2019.01.074

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 51

Metadata

Authors
Wells, Q. S., Gupta, D. K., Smith, J. G., Collins, S. P., Storrow, A. B., Ferguson, J., Smith, M. L., Pulley, J. M., Collier, S., Wang, X., Roden, D. M., Gerszten, R. E., & Wang, T. J.
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2019-05
Volume
73
Issue
17
Pages
2195-2205
ISSN
0735-1097 (ISSN-L)
OpenAlex
W2942868820
Cited by
51
References
3
FWCI
4.24
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Accelerating Biomarker Discovery Through Electronic Health Records, Automated Biobanking, and Proteomics. https://app.cochat.ai/papers/10.1016/j.jacc.2019.01.074
The paper
Wells, Q. S., Gupta, D. K., Smith, J. G., Collins, S. P., Storrow, A. B., Ferguson, J., Smith, M. L., Pulley, J. M., Collier, S., Wang, X., Roden, D. M., Gerszten, R. E., & Wang, T. J. (2019). Accelerating Biomarker Discovery Through Electronic Health Records, Automated Biobanking, and Proteomics. Journal of the American College of Cardiology. https://doi.org/10.1016/j.jacc.2019.01.074

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.